Teriparatide (& biosimilars)
- BNF:
- 6.6.1
- Status:
- Red
- Decision Date:
- October 2019
Comments
Treatment of osteoporosis in postmenopausal women and men at increased risk of fracture.
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
search again